Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
- Exclusive license via Yeda to two Weizmann Institute patent families from Prof. Nir London’s lab, a leader in covalent drug design
- Site-specific, durable and traceless protein radiolabeling approaches intended to enhance tumor selectivity and retention in radiopharmaceuticals
- Integration into Actithera’s platform to support design of next-generation radioligand therapies across oncology indications
Cambridge, MA and Oslo, Norway – 14 October 2025 – Actithera, a biotechnology company pioneering next-generation radiopharmaceutical therapies, today announced an exclusive license agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for two patent families covering breakthrough covalent chemistry technologies. Actithera will apply these innovations to advance its proprietary platform for radiopharmaceutical drug discovery and development.
